Development of a High-Throughput Three-Dimensional H&E Platform for the Characterization of Breast Cancer Biopsies
Award amount
$280,000Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Visikol, Inc.
- Proposal award date
- 2018-05-01
- Contract end date
- 2019-04-30
- UEI
- E92DHV41MJE3
- Solicitation number
- PA19-029
- Topic code
- 102
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development of a 3D Imaging Diagnostic Tool for the Improved Characterization of Metastatic Melanoma
- SBIR Phase II: Digitization of Skeletal Evaluations for Developmental and Reproductive Toxicology (DART) Studies.
- Improved Characterization of 3D In Vitro Cell Culture Assays for the Drug Discovery Process
- SBIR Phase I: Digitization of Skeletal Evaluations for Developmental and Reproductive Toxicology (DART) Studies.
- SBIR Phase I: Improved Skeletal Visualization Technology for Developmental and Reproductive Toxicology (DART) Studies
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use
- Modex, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer
- Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas
- Allogeneic cell and gene therapy for neuroendocrine tumors
- Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer
Research funding history
6 SBIR/STTR records share this UEI (2016–2021). Reported award amounts total $3,334,045. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II, Phase II
Agencies: Department of Health and Human Services, National Science Foundation